Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors

Abstract excerpt

Small molecule inhibitors of dual specificity, tyrosine phosphorylation-regulated kinase 1A (DYRK1A), including harmine and others, are able to drive human β cell regeneration. While DYRK1A is certainly a target of this class, whether it is the only or the most important target is uncertain. Here, we employ a combined pharmacologic and genetic approach to refine the potential mitogenic targets of the DYRK1A...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Diabetes Management and Research
• Share to Genetics and Neurodevelopmental Disorders
• Share to Pancreatic function and diabetes